MyMelanoma study selected to join NHS DigiTrials initiative — University of Oxford, Medical Sciences Division

Launched in 2023, the MyMelanoma study is the most ambitious melanoma research project undertaken in the UK. Led by the University of Oxford and managed through Oxford Cancer, it aims to recruit 20,000 UK melanoma patients in order to carry out the largest study of melanoma ever performed, to improve understanding of melanoma skin cancer and its treatment.

MyMelanoma has been selected as one of three cancer-focussed studies (alongside a fourth seeking to improve the care of young children needing complex surgery) to pilot the new NHS DigiTrials recruitment service, which is managed by NHS England. The service aims to identify NHS patients who might be suitable for a certain trial and contacts them to see if they would like to take part.

Commenting on the news, Professor Mark Middleton, Chief Investigator of MyMelanoma, Head of the Department of Oncology and Co-Director of Oxford Cancer, said:

“Being chosen as one of 4 studies to pilot the NHS’s DigiTrials recruitment service is an amazing opportunity for MyMelanoma and the patients with whom we work. Our partnership will let us offer patients all around the country both the chance to take part in research into melanoma, and to have a say in how that research is done. It will help make MyMelanoma the largest ever melanoma study and let us answer research questions we simply couldn’t tackle before, with the goal of providing a more individualised approach to patient care”.

Read the full story on the Oxford Cancer website.